Lawrence Livermore National Laboratory

Lab researchers aid COVID-19 response in antibody, anti-viral research

24-Mar-2020 2:40 PM EDT, by Lawrence Livermore National Laboratory

Newswise — Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.

Backed by five high performance computing (HPC) clusters and years of expertise in vaccine and countermeasure development, a COVID-19 response team of LLNL researchers from various disciplines has used modeling & simulation, along with machine learning, to identify about 20 initial, yet promising, antibody designs from a nearly infinite set of potentials and to examine millions of small molecules that could have anti-viral properties. The candidates will need to be synthesized and experimentally tested — which Lab researchers cautioned could take time — but progress is being made.

“For several decades, the Laboratory has been at the forefront of protecting the country against biological threats of any type,” said Lab Senior Science Adviser Dave Rakestraw, who formerly ran LLNL’s biodefense programs and is coordinating the Lab’s COVID-19 technical response. “We’ve been putting a large amount of focus for the last six years on applying  the computational resources at LLNL to try to accelerate the timescales for developing a response to an emerging biological threat. We’ve done that by using our extensive computational capabilities (staff and computer infrastructure) and developing partnerships with universities, drug companies and tech companies. That effort has put us in a position where we have tools now that are applicable to helping with the current response.”

When the COVID-19 outbreak began, LLNL’s Adam Zemla developed and published a predicted 3D protein structure of the virus, which was downloaded and used by more than a dozen outside research groups. Since then, the actual crystal structure of the key protein from SARS-CoV-2, the virus that causes COVID-19, has been determined, which closely matched the team’s predictions, researchers said.

Armed with the virus’ predicted 3D structure and a few antibodies known to bind and neutralize SARS, an LLNL team led by Daniel Faissol and Thomas Desautels used two HPC clusters to perform AI-driven virtual screening of antibodies capable of binding to SARS-CoV-2, generating high-fidelity simulations to test the molecular interactions for efficacy. The modeling platform, supported by the Defense Advanced Research Projects Agency (DARPA) and internal Laboratory Directed Research and Development (LDRD) funding, is the first of its kind in integrating experimental data, structural biology, bioinformatic modeling and molecular simulations – driven by a machine learning algorithm – to design antibody candidates. This platform was used to identify potential high value modifications to the SARS antibodies so that it binds to SARS-CoV-2.

“Our approach, while still being developed, is aimed at designing high quality antibody therapeutics or vaccines in extremely rapid time-scales for scenarios in which waiting for many rounds of time-consuming experimental steps is not an option,” said Faissol. “Experimental data and structural bioinformatics are important components to enable high-quality predictions, but integrating machine learning and molecular simulations on HPC are the key to enabling the speed and scalability we need to search and evaluate huge numbers of possible antibody designs.”

The approach has not only sped up the process considerably over selection guided solely by human intuition — narrowing down the number of antibody candidates from 1039 possibilities to a handful in a matter of weeks — but also has focused on areas where scientists may not have otherwise looked.

 “Now we’re not just searching blindly; we’re actually creating structures that we think are in the proper part of the design space, then we do our evaluations on those,” said Jim Brase, the Laboratory’s deputy associate director for Data Science. “We’ll get novelty, and — we hope — a higher percentage of real validated answers out of this approach at the end.”

Researchers said they are just beginning to look at the data and are currently working to arrange synthesis, as well as set up testing and evaluation  of the designs, through both internal efforts and targeted external collaborations..

Antiviral drug design

Another component of the multi-pronged response involves antiviral drug design. A group of Lab scientists led by Felice Lightstone and Jonathan Allen recently used dedicated access time on the entire Quartz supercomputing cluster to perform virtual screening of small molecules against two COVID-19 proteins. Using LLNL-customized software, created by Lab scientist Xiaohua Zhang, the LLNL team has performed a large-scale computational run to screen 26 million molecules against four protein sites (totaling more than 100 million docking calculations) to identify compounds that possibly could prevent infection or treat COVID-19. 

“Using the computational tools and data that we created from our American Heart Association’s Center for Accelerated Drug Discovery, we were able to computationally screen these molecules so quickly and at such a large scale,” Lightstone said. “This is the first step toward finding a new antiviral. We developed a whole pipeline for drug design and plan to continue in the coming weeks, ending with experimental testing of the predicted molecules.  This should speed up the drug design process.”

Some models being used to determine the molecules’ safety are derived from the system developed through the multi-institutional ATOM (Accelerating Therapeutics for Opportunities in Medicine) consortium, a project aimed at speeding up cancer drug discovery. That work has helped the Lab evaluate molecules in a timely manner and produce models useful for any outbreak, researchers said.

Need for DOE lab capabilities

LLNL scientists called the COVID-19 pandemic a “wake-up call” signifying the need for a longer-term investment and sustained government-wide effort, particularly in applying high performance computing to personalized medicine. 

“It has clarified the need for and value of leadership Department of Energy capabilities,” said Shankar Sundaram, director of LLNL’s Center for Bioengineering. “The Laboratory anticipated this kind of situation in pursuing a predictive biology initiative. The reason we were able to jump onto this quickly was not just because we had the capabilities, but because we’ve been thinking about these scenarios for a long time.”

LLNL is also adapting its portable, rapid PCR-based molecular diagnostics platform (Bio ID) developed by LLNL biomedical scientist Larry Dugan as a potential tool to quickly diagnose COVID-19.

The overall COVID-19 response effort involves all 17 DOE national laboratories. LLNL’s response team includes scientists and engineers from the Lab’ Center for Bioengineering, Forensic Science Center and Biodefense Knowledge Center (BKC), Biosciences and Biotechnology Division, and the HPC capabilities of cluster systems Quartz, Lassen, Corona, Pascal and Catalyst.

Filters close

Showing results

1120 of 2869
Newswise:Video Embedded give-and-take-during-the-pandemic
Released: 11-Aug-2020 12:35 PM EDT
Give and Take during the Pandemic
The Electrochemical Society

The pandemic sent shockwaves through the academic community. Some institutions are weathering the storm better than others. At Lewis University (LU), Professor Jason Keleher and his students, Carolyn Graverson, Abigail “Abby” Linhart, and Katie Wortman-Otto, are optimistic. In our series, The ECS Community Adapts and Advances, they share their COVID-19 experiences and hopes for the future.

Newswise: Story Tips From Johns Hopkins Experts on COVID-19
Released: 11-Aug-2020 11:55 AM EDT
Story Tips From Johns Hopkins Experts on COVID-19
Johns Hopkins Medicine

Recently, several physicians hosted a press conference in which one physician claimed that the combination of hydroxychloroquine, the antibiotic azithromycin and the mineral zinc could cure COVID-19. The video footage of that press conference went viral on social media, and soon many social media platforms removed the videos for providing inaccurate, non-scientifically backed claims. But questions from the public may still remain.

Newswise: Will the COVID-19 pandemic give a permanent boost to telemedicine for epilepsy care?
Released: 11-Aug-2020 11:45 AM EDT
Will the COVID-19 pandemic give a permanent boost to telemedicine for epilepsy care?
International League Against Epilepsy

Telemedicine for epilepsy care is more popular than ever. It has many advantages—but can it sustain itself into the future?

Newswise: Managing Children’s Back-to-School Anxiety
Released: 11-Aug-2020 11:20 AM EDT
Managing Children’s Back-to-School Anxiety
Rutgers University-New Brunswick

A Rutgers mental health expert discusses how to prepare children to return to school, signs of emotional distress and benefits of virtual learning

Newswise: NYC shoppers 4 times more likely to frequent stores adhering to social distance guidelines
Released: 11-Aug-2020 11:15 AM EDT
NYC shoppers 4 times more likely to frequent stores adhering to social distance guidelines
Cornell University

New York City residents are four times more likely to choose a store where shoppers respect 6 feet of distancing than one where no one is social distancing, according to a Cornell University experiment using 3D simulation.

Newswise: Why Does COVID-19 Impact Only Some Organs, Not Others?
7-Aug-2020 10:55 AM EDT
Why Does COVID-19 Impact Only Some Organs, Not Others?
American Institute of Physics (AIP)

In severe cases of COVID-19, damage can spread beyond the lungs and into other organs, such as the heart, liver, kidney and parts of the neurological system. Beyond these specific sets of organs, however, the virus seems to lack impact. Ernesto Estrada aimed to uncover an explanation as to how it is possible for these damages to propagate selectively rather than affecting the entire body. He discusses his findings in the journal Chaos.

Newswise: Masks, PPE Materials Should Be Hydrophilic
5-Aug-2020 10:05 AM EDT
Masks, PPE Materials Should Be Hydrophilic
American Institute of Physics (AIP)

Since the COVID-19 virus spreads through respiratory droplets, researchers in India set out to explore how droplets deposited on face masks or frequently touched surfaces dry. Droplets can be expelled via the mouth or nose and studies have shown a substantially reduced chance of infection once they dry. In Physics of Fluids, the researchers publish their findings that surface wetting properties to reduce the drying time of droplets could help lessen the risk of infection from coronaviruses.

Released: 11-Aug-2020 9:00 AM EDT
School spending cuts? Citizens prefer teachers and administrators to take the hit during economic crises
Binghamton University, State University of New York

With schools around the world looking into various cost-cutting measures in the midst of the COVID-10 pandemic, new research from Binghamton University, State University of New York reveals that citizens prefer teachers and administrative staff to be at the frontline of school spending cuts during times of economic crisis.

Newswise: Researchers Create Mask Filtration Effectiveness Hierarchy
11-Aug-2020 9:00 AM EDT
Researchers Create Mask Filtration Effectiveness Hierarchy
University of North Carolina School of Medicine

Infection prevention experts at the UNC Medical Center set out to gather evidence on the fitted filtration efficiency of dozens of different types of masks and mask modifications, including masks sterilized for reuse, expired masks, novel masks sourced from domestic and overseas sources, and homemade masks.

Newswise: Researchers find clues to SARS-CoV-2 infection and explore why COVID-19 impacts patients differently
Released: 11-Aug-2020 8:40 AM EDT
Researchers find clues to SARS-CoV-2 infection and explore why COVID-19 impacts patients differently
McMaster University

Previously, scientists have determined that entry of SARS-CoV-2 into cells occurs through a receptor on the cell surface, known as ACE2. But the McMaster-Waterloo team has found that the ACE2 receptor is at very low levels in human lung tissue.

Showing results

1120 of 2869